SAB Biotherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SABS, updated each market day.
SABS AI Sentiment
AI sees no strong directional signal for SAB Biotherapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sector
Exchange
Market Cap
$267,047,713
Cap Tier
Employees
86
Headquarters
MIAMI BEACH, FL
Listed Since
Oct. 22, 2021
Website
SABS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SABS Volatility
SAB Biotherapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
